California stem-cell agency shifts toward clinical work

At least we have one state that is working in the right direction. I have no idea how to influence this agency to work on neurons. California readers, some help here.
http://blogs.nature.com/news/2012/05/california-stem-cell-agency-shifts-toward-clinical-work.html
I only copied the first 4 paragraphs.
The California Institute of Regenerative Medicine (CIRM) voted on 24 May to accept a new strategic plan which shrinks or eliminates support for basic research, facilities and training, while funneling more of its funds toward clinical development. “The first stage of CIRM was really exploring the field,” said Ellen Feigal, senior vice president of R&D. “The next five years should be one of more focus.” By July 2013, the agency hopes to have two programmes approved for clinical trials in the United States.
During the past five years, nearly half of the approximately $1.3 billion awarded by the agency went toward building new research facilities and training and career development. Looking ahead, of the approximately $840 million to be awarded  over the next five years, about three fifths is slotted to go toward development research,  preparing stem cell-based therapeutics for clinical testing, with much of the rest devoted to translational and basic research. (An additional $650 million has been approved but not awarded; allocation is roughly an average between previously awarded funds and future plans.)
No one spoke during a call for comments from the general public, and the plan was approved by a voice vote with no objections. Board member Jeff Sheehy voiced concerns about cutting off training and basic research. CIRM president Alan Trounson and Ellen Feigal said that the exact allocations could be determined at future meetings. There was general acknowledgement that difficult funding decisions are ahead. “We are now in the realm of trade-offs,” said Sheehy.
Also today, CIRM announced $69 million of grants for translational research. “With these new awards, the agency now has 52 projects in 33 diseases at varying stages of working toward clinical trials,” said Jonathan Thomas, governing board chair, said in a statement.